Research in Pharmaceutical Sciences

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 15  |  Issue : 4  |  Page : 381--389

Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function


Hamid Bakherad1, Neda Setayesh2, Seyed Latif Mousavi Gargari3, Walead Ebrahimizadeh4, Faranak Mavandadnejad2, Elnaz Faghfuri5, Soheila Ebrahimi2, Mohammad Heiat6, Mona Shahpari2, Zargham Sepehrizadeh2 
1 Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
2 Department of Pharmaceutical Biotechnology and Pharmaceutical Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. Iran
3 Department of Biology, Faculty of Basic Science, Shahed University, Tehran, I.R. Iran
4 Department of Surgery, Division of Urology, McGill University and the Research Institute of the McGill University Health Centre (RI MUHC), Montreal, Quebec, Canada
5 Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, I.R. Iran
6 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran

Correspondence Address:
Hamid Bakherad
Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan
I.R. Iran
Zargham Sepehrizadeh
Department of Pharmaceutical Biotechnology and Pharmaceutical Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
I.R. Iran

Background and purpose: Granulocyte colony-stimulating factor (G-CSF) is routinely used in combination with chemotherapy to battle neutropenia. However, studies suggest that this chemokine may increase the risk of metastasis and malignancy in many cancers. To counteract the adverse effects of G-CSF in cancer, antibodies have been used to block its action. However, antibodies are large and complex molecules which makes their production expensive. Thus in this study, we aim to construct different structure variants of the G-CSF receptor containing different domains and select the best variant that prevents the adverse actions of this chemokine. These novel structures are smaller than antibodies and easier to produce. Experimental approach: Different domains of the G-CSF receptor were designed and cloned into the pET28a expression vector. These recombinant receptor subunits were then expressed in Escherichia coli and purified using standard affinity chromatography techniques. Interaction of recombinant receptor subunits with G-CSF was assessed using enzyme-linked immunosorbent assay and NFS60 cells. Findings / Results: Two recombinant receptor subunits containing D1 + D2 + D3 domains and D2 domain showed the strongest inhibitory activity to G-CSF. Conclusion and implications: These novel recombinant receptor variants could be candidates for further studies in the development of novel therapeutics.


How to cite this article:
Bakherad H, Setayesh N, Mousavi Gargari SL, Ebrahimizadeh W, Mavandadnejad F, Faghfuri E, Ebrahimi S, Heiat M, Shahpari M, Sepehrizadeh Z. Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function.Res Pharma Sci 2020;15:381-389


How to cite this URL:
Bakherad H, Setayesh N, Mousavi Gargari SL, Ebrahimizadeh W, Mavandadnejad F, Faghfuri E, Ebrahimi S, Heiat M, Shahpari M, Sepehrizadeh Z. Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function. Res Pharma Sci [serial online] 2020 [cited 2020 Oct 27 ];15:381-389
Available from: https://www.rpsjournal.net/article.asp?issn=1735-5362;year=2020;volume=15;issue=4;spage=381;epage=389;aulast=Bakherad;type=0